Talent Pool

Contributed by:

PharmaVOICE Staff

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Biopharma pool

PV0316_MarkAllesMark Alles
Dr. Jacqualyn Fouse
Bob Hugin
Scott Smith
Celgene Strengthens Leadership Team
Celgene has made several organizational changes to strengthen its leadership team and position the company for long-term growth.

Mark Alles has been promoted to CEO. Mr. Alles is a three-decade industry veteran and has been with Celgene since 2004, most recently serving as president and chief operating officer during which time he integrated Celgene’s corporate operational functions in support of its global commercial franchises. Before serving as president and chief operating officer, he built and led Celgene’s hematology and oncology franchise.

Jacqualyn Fouse, Ph.D., has been promoted to president and chief operating officer (COO). Dr. Fouse joined Celgene in 2010 as chief financial officer and has excelled as both the leader of Celgene’s finance department and in her current role as president of Celgene’s hematology and oncology franchise. Dr. Fouse is charged with further enhancing Celgene’s commitment to operational excellence and driving exceptional performance across Celgene’s franchises and functions.

Bob Hugin has been named executive chairman. He continues to lead the board of directors and manage the strategic direction of the company.
Scott Smith, president of Celgene’s I&I franchise, has been appointed to chair Celgene’s global management committee, where he is responsible for the effective coordination of Celgene’s operational and strategic imperatives.

PV0316_RinkoGhoshRinko Ghosh
Symic Names President and Chief Business Officer
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), has appointed Rinko Ghosh as president and chief business officer.

Previously, Mr. Ghosh was senior VP and chief business officer at Nektar Therapeutics.

Dr. Richard McCloskey
PV0316_DrMcCloskeyRenova Therapeutics Appoints Lead for Clinical Development
Richard “Mac” McCloskey, M.D., joins Renova Therapeutics as executive VP of clinical development responsible for all clinical aspects of the company’s trials, including preparation of trial synopses and protocols, review and approval of case report systems and safety reporting, and drafting of clinical trial endpoints. Renova Therapeutics is a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases.

Chris Rivera
PV0316_ChrisRiveraNativis Names New Chairman,
President, and CEO
Nativis, a clinical-stage bioelectronics company developing non-invasive therapies for cancers and other serious diseases, has named Chris Rivera chairman, president, and CEO. Mr. Rivera has served as a director of the company since 2013 and brings 30 years of biotechnology industry experience to Nativis.

Mr. Rivera’s career highlights include founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015.

PV0316_MarySzelaMary Szela
Aegerion Pharmaceuticals Names CEO
Aegerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Mary Szela CEO. Ms. Szela brings 27 years of progressive leadership experience to Aegerion as well as valuable expertise building global billion-dollar brands, such as Humira, and advancing pipeline products in the biotechnology and pharmaceutical industries. Most recently, Ms. Szela was CEO of Melinta Therapeutics.

Specialty Pool

PV0316_DrIndranilNandiDr. Indranil Nandi
Vertice Pharma appoints VP, Research & Development
Vertice Pharma, a specialty pharmaceuticals company focused on improving patients’ health, has appointed Indranil Nandi, Ph.D., as VP, research and development. Most recently, Dr. Nandi has served as VP, generic R&D, for Impax Laboratories.
Jeff Mihm
Noven Appoints CEO
PV0316_JeffMihmJeff Mihm has been appointed Noven’s CEO, succeeding Jeffrey Eisenberg. Mr. Mihm joined Noven in 2003 and since then has been consistently promoted to senior leadership positions of increasing scope and importance. Most recently, he served as VP, chief administrative officer and general counsel, where he oversaw Noven’s business development, corporate affairs, human resources, information technology, and legal/compliance functions.

Noven is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products.

 Agency Pool

PV0316_BillMcEllenBill McEllen
Fingerpaint Taps Agency Veteran
for NY Office
Fingerpaint, a full-service marketing agency, has appointed Bill McEllen to lead its New York office. Mr. McEllen brings more than 20 years of experience in client-side sales, marketing, and advertising, as well as an innate ability to combine corporate objectives with creative strategies to produce impactful campaigns. Mr. McEllen joins Fingerpaint after 13 years with McCann where he served as president of both the Torre Lazur and Echo Torre Lazur Groups.

PV0316_HoracioRodriguezHoracio Rodriguez
Ashfield Adds to
Leadership Team
Ashfield, part of UDG Healthcare, has named Horacio Rodriguez VP of clinical and commercial contact center US in its Ivyland, Pa., office. Mr. Rodriguez has more than 25 years of commercial healthcare experience in pharmaceutical sales, brand marketing, and contact center management within oncology, neurology, endocrinology, gastroenterology, cardiovascular, and asthma. He was VP of healthcare commercial and medical operations US for TeleRx. (PV)

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK